Todas las noticias

Spineway’s total revenue for the first half of 2023 was €5.4 million, up 75% compared with the first half of 2022. Growth was driven mainly by the contribution of sales of Spine Innovations, acquired in July 2022. However, organic growth1 remained sustained, representing 12% in the first half of 2023, thanks to the steep increase in Distimp sales (+66%), demonstrating the momentum spurred by the Group’s commercial activity over the period.

Spineway, a specialist in innovative implants for the treatment of severe disorders of the spinal column, has been on a new growth trajectory for more than a year, driven by the acquisitions of Distimp in June 2021 and Spine Innovations in July 2022. These acquisitions have enabled it to extend its geographical footprint, to offer two operating techniques – fusion and non-fusion – and to stimulate product innovation

Spineway has achieved a total revenue of €2.4 million as of Q1 2023, representing growth of 79% compared with Q1 2022, mainly driven by sales of Spine Innovations’ disc prostheses. Adjusted for this contribution, quarterly revenue remainsrobust and represents an all-time high of €1.4 million despite a temporary delay in Latin America due to regulatory procedures for the approval of new products.

The Ordinary and Extraordinary General Meeting of Spineway's shareholders was held on first call on Tuesday, April 4, 2023 at 11:00 a.m. at the Group's registered office, 7 allée Moulin Berger in Ecully (69)

Spineway informs its shareholders that they are invited to attend the Combined General Meeting to be held on Tuesday, April 4, 2023 at 11:00 a.m. at the Group's headquarters, 7 allée Moulin Berger in Ecully (69).

2022 illustrates the strong momentum generated by management, combining targeted external growth, international business development and the acceleration of an ambitious R&D program aimed at making the Group a reference player in spine surgery with Premium positioning.

SPINEWAY (ISIN : FR0011398874 – ALSPW), a specialist in innovative implants for the treatment of severe spine pathologies, announced today its 2023 financial calendar.

In addition to a commercial performance, this exercise confirms the relevance of our mixed growth strategy combining organic growth and targeted acquisitions. The synergies implemented through the acquisition of Distimp in 2021 and Spine Innovations in 2022 are reflected in our sales by significantly strengthening our key geographic positions and our premium product lines.

At the largest scientific and commercial European congress dedicated to spinal surgery, which this year brought together almost 2,000 surgeons from around the world, Spineway was able to present its flagship instruments and implants (Mont-Blanc, Mont-Blanc MIS and Twin Peaks), three new ranges of Group spinal implants : Kaphorn, Veos, Acifbox and the two models of cervical and lumbar ESP disc prosthesis from Spine Innovations.